IDiyas

For the Inventor, By the Inventor

East Haddam, CT, United States of America

Ivar M McDonald

USPTO Granted Patents = 24 

Average Co-Inventor Count = 6.9

ph-index = 5

Forward Citations = 71(Granted Patents)


Location History:

  • East Haddam, CT (US) (2011 - 2022)
  • Woodstock, CT (US) (2020 - 2023)

Company Filing History:

goldMedal23 out of 3,681 
 
Bristol-myers Squibb Compnay
 patents
silverMedal2 out of 46 
 
Roche Innovation Center Copenhagen A/s
 patents
bronzeMedal1 out of 1,186 
 
The Scripps Research Institute
 patents
4. 1 out of 41 
 
Bristol Meyers Squibb Company
 patents
where one patent can have more than one assignee

Years Active: 2011-2023

Loading Chart...
24 patents (USPTO):
1. 11713316 - Substituted naphthyridinone compounds useful as T cell activators (2023-08-01),
2. 11613554 - Phosphorous (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (V) compounds (2023-03-28),
3. 11447775 - Antisense oligonucleotides targeting alpha-synuclein and uses thereof (2022-09-20),
4. 11359197 - Antisense oligonucleotides targeting alpha-synuclein and uses thereof (2022-06-14),
5. 11058767 - CAMK2D antisense oligonucleotides and uses thereof (2021-07-13),
6. 10954238 - Substituted naphthyridinone compounds useful as T cell activators (2021-03-23),
7. 10869934 - Antiproliferative compounds and conjugates made therefrom (2020-12-22),
8. 10669272 - Substituted naphthyridinone compounds useful as T cell activators (2020-06-02),
9. 10398783 - Antiproliferative compounds and conjugates made therefrom (2019-09-03),
10. 10112975 - Benzodiazepine dimers, conjugates thereof, and methods of making and using (2018-10-30),
11. 9822144 - Benzodiazepine dimers, conjugates thereof, and methods of making and using (2017-11-21),
12. 9822112 - Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using (2017-11-21),
13. 9796713 - Tricyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands (2017-10-24),
14. 9708323 - Tricyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands (2017-07-18),
15. 9676794 - Benzodiazepine dimers, conjugates thereof, and methods of making and using (2017-06-13),

Title: Ivar M McDonald: Innovator in Therapeutic Compounds

Introduction

Ivar M McDonald is an accomplished inventor based in East Haddam, Connecticut, holding an impressive portfolio of 24 patents. He has made significant contributions in the field of pharmaceutical chemistry, particularly in developing compounds that have potential therapeutic applications.

Latest Patents

Among his latest innovations is a patent for substituted naphthyridinone compounds, which serve as T cell activators. These compounds, defined by a specific formula, are designed to inhibit the activity of diacylglycerol kinases, with promising applications in treating viral infections and various proliferative disorders such as cancer. Additionally, he has developed novel phosphorous (V)-based reagents and methods for creating stereo-defined organophosphorous (V) compounds, showcasing his creativity and expertise in chemical methods that could advance therapeutic development.

Career Highlights

Throughout his career, Ivar has made notable advancements while working with leading companies in the pharmaceutical industry. He has held positions at Bristol-Myers Squibb Company and Roche Innovation Center Copenhagen A/S, where he has applied his innovative ideas to real-world challenges in medicine. His extensive patent portfolio reflects his dedication to improving healthcare solutions.

Collaborations

Ivar has collaborated with accomplished professionals in his field, including Richard E Olson and Naidu S Chowdari. These collaborations have likely contributed to the breadth and success of his research, allowing for the exchange of ideas and enhancement of innovative approaches to complex scientific problems.

Conclusion

Ivar M McDonald exemplifies the impact of dedicated inventors in advancing medical science through innovation. With his extensive patent portfolio and collaborative efforts, he continues to contribute to the development of new therapeutics that hold the potential to improve patients' lives. His work serves as an inspiration to other inventors and researchers in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…